Documenting the Re-Consent Process with Patients in Clinical Trials

Published on 22/12/2025

How to Properly Document the Re-Consent Process with Patients in Clinical Trials

In clinical trials, re-consenting participants is often necessary due to protocol amendments, safety updates, or changes in legal status. However, equally important is the thorough documentation of this re-consent process. Regulatory agencies like the USFDA, EMA, and CDSCO require accurate, verifiable, and version-controlled records of participant consent activities, including any re-consent events. This tutorial provides detailed guidance for documenting re-consent ethically and compliantly.

Table of Contents

Why Accurate Re-Consent Documentation Matters:

Ensures participant understanding and agreement to updated study terms
Maintains compliance with GMP documentation practices
Demonstrates adherence to ICH-GCP and local ethics requirements
Prepares sites for regulatory inspections and sponsor audits
Prevents legal or ethical concerns from incomplete records

Key Elements of Re-Consent Documentation:

1. Updated Informed Consent Form (ICF)

Must include new version number and date
Clearly indicate the changes from previous version (preferably tracked)
Approved by IRB/EC before use
Signed and dated by participant and site staff

2. Re-Consent Log

A site-level tracker that includes:

Subject ID
Old ICF version and date
New ICF version and date
Date re-consent was taken
Staff initials or signature
Remarks (e.g., “consented in follow-up visit 3”)

3. Source Documentation

Include an entry in the subject’s source notes (paper or EHR)
State the

reason for re-consent (e.g., “subject re-consented due to protocol amendment v5.0”)

Indicate ICF version, date, and staff identity

Any issues (e.g., patient refused or needed clarification) should be documented

4. Audio-Visual (AV) Consent Recording (India-specific)

As per CDSCO requirements, AV re-recording may be needed for significant changes in ICF:

Use secure devices with date/time stamps
Store recordings in access-controlled folders
Note AV recording ID in source documentation

5. TMF and Investigator Site File (ISF) Filing

Updated signed ICF copies filed in both participant binder and ISF
Maintain both old and new versions for audit trail
Cross-reference in re-consent tracker and protocol amendment log

Step-by-Step Re-Consent Documentation Process:

Step 1: Receive Approved Revised ICF

Obtain Ethics Committee-approved version and distribute to appropriate staff. Use SOP templates for pharma sites to manage version rollout.

Step 2: Re-Consent the Participant

Explain the changes, reason for re-consent, and answer questions
Get participant’s signature and date on new ICF
If LAR is involved, ensure appropriate witness (if required)

Step 3: Record in Source Documentation

Make an entry in the subject’s clinical notes or CRF. For example: “Subject re-consented with ICF version 5.0 dated 12-March-2025 due to protocol changes involving dose escalation. AV recording completed. Signed by Dr. A. Verma.”

Step 4: Update Logs and Systems

Update ICF tracker, CRF eConsent module (if applicable), and re-consent audit trail log
File signed ICF in source and ISF within 24 hours
Notify monitor during next SDV or interim visit

Common Documentation Errors and How to Avoid Them:

Error	Consequence	Prevention Strategy
ICF not signed by participant	Consent invalid; potential protocol deviation	Check ICF before participant leaves site
AV recording missing	Non-compliance with national requirements	Use re-consent AV checklist and logs
Incorrect ICF version used	Trial data invalid for that subject period	Destroy outdated versions; maintain a version control binder
Source documentation absent	GCP non-compliance during audit	Use structured source templates for re-consent

Re-Consent Checklist for Documentation:

☑ Correct and current ICF version used
☑ Signature/date from participant (and LAR if required)
☑ Staff signature and printed name
☑ Entry made in source notes
☑ AV recording completed and logged (if applicable)
☑ ICF filed in source and ISF
☑ Updates made in ICF tracker and CTMS

Regulatory Tips and Best Practices:

Include consent audit logs as part of monitoring reports
Use color-coded ICFs or headers to easily identify current versions
Schedule periodic reviews to archive outdated versions systematically
Maintain digital and paper trails for redundancy

Digital Consent Tools and Their Role:

Many sites are transitioning to electronic consent (eConsent) systems, which facilitate version tracking, time stamping, and remote audit readiness. Ensure your system meets FDA 21 CFR Part 11 or EMA Annex 11 compliance requirements.

Conclusion:

Documenting the re-consent process is as critical as obtaining the consent itself. Thorough, timely, and compliant documentation ensures ethical standards are upheld and protects both participants and research teams. Whether using paper forms, AV tools, or digital systems, always prioritize clear, traceable records for every re-consent interaction in your clinical trial.